Price | Targeted cancer therapy with tyrosine kinase inhibitors

Price

Tyrosine kinase inhibitors are active ingredients from the group of genetically engineered monoclonal antibodies. This newer, targeted treatment of cancer is still very expensive. As a rule, it is a long-term or even life-long therapy to suppress a relapse. Glivec (contains the active ingredient Imatinib) in the therapy of chronic myeloid leukemia costs over 1,500 € in the 60 piece tablet pack, with 100 mg active ingredient per film-coated tablet.

Alternatives to tyrosine kinase inhibitors

In the therapy of chronic myeloid leukemia, the tyrosine kinase inhibitor imatinib is part of the first-line therapy, especially when a specific genetic mutation is present. If the patient responds poorly to the drug, the dose is initially doubled. Another option is the combination with interferon alpha.

If the standard therapy is unsuccessful, a transplantation of stem cells from family donors or foreign donors is usually performed. For other types of cancer, alternatives to immunotherapy with tyrosine kinase inhibitors are classical chemotherapy with various drugs, the cytostatic drugs, or radiation therapy. The treatment regimen depends on the disease and individual factors. If you are interested in classical chemotherapy as an alternative to tyrosine kinase If you would like to learn more about stem cell transplantation as an alternative therapy for leukemia, we recommend our page on: Stem Cell Transplantation If you would like to learn more about stem cell transplantation as an alternative therapy for leukemia, we recommend our page on: Stem Cell Transplantation